作者投稿
专家审稿
编辑办公
邮件订阅
RSS
-
-
世界初级创伤救治(Primary Trauma Care，PTC)理事会于2012年3月28日在阿根廷首都布宜诺斯艾利斯市召开了理事会议，来自卫生部医院管理研究所的阎赢主任和霍添琪，北京协和医院急诊科于学忠教授、王仲教授和麻醉科黄宇光教授出席了此次会议。会议回顾了PTC在全球近50个国家开展工作的情况，包括PTC在中国实施的成功经验。在卫生部医政司和医院管理研究所的领导下，PTC理事会与中国医师协会急诊医师分会、麻醉学医师分会联手合作，自2010年9月5日在中国成功启动PTC，至今已经在全国15个省份为2000多家医院培训了6000多名医学专业人员，取得了良好的培训效果。北京协和医院作为中国医师协会急诊医师分会和麻醉学医师分会的会长单位，为该项目做出了积极贡献。作为PTC理事，黄宇光教授代表中方团队介绍了PTC多学科全方位合作的中国模式。目前中国已经成为PTC项目培训在全球规模最大的国家，受到各位PTC理事和与会代表的好评。会议对如何促进PTC项目持续发展和相关教材的修订进行了讨论，并且决定PTC世界大会将于2013年在中国召开。
(卫生部医院管理研究所 霍添琪)
-
[1] Genant HK, Mall JC, Wagonfeld JB, et al. Skeletal demineralization and growth retardation in inflammatory bowel disease [J]. Invest Radiol, 1976, ll:541-549. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=WK_LWW201705250614429
[2] Noble CL, McCullough J, Ho W, et al. Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2008, 27 : 588-596. DOI: 10.1111/j.1365-2036.2008.03599.x
[3] Poliak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease[J]. Am J Gastroenterol, 1998, 93 : 1483-1490. DOI: 10.1111/j.1572-0241.1998.468_q.x
[4] Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease[J]. Gut, 1997, 40:228-233. DOI: 10.1136/gut.40.2.228
[5] Card T, West J, Hubbard R, et al. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study[J]. Gut, 2004, 53:251-255. DOI: 10.1136/gut.2003.026799
[6] Van Staa TP, Leufkens HG, and Cooper C. The epidemiology of corticosteroid-induced osteoporosis : a meta-analysis[J]. Osteoporos Int, 2002, 13:777-787. DOI: 10.1007/s001980200108
[7] Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease[J]. Eur J Gastroenterol Hepatol, 2003, 15:857-864. DOI: 10.1097/00042737-200308000-00004
[8] Manolagas SC. The role of IL-6 type cytokines and their receptors in bone[J]. Ann N Y Acad Sci, 1998, 840: 194-204. DOI: 10.1111/j.1749-6632.1998.tb09563.x
[9] Schulte CM, Dignass AU, Goebell H, et al. Genetic factors determine extent of bone loss in inflammatory bowel disease [J]. Gastroenterology, 2000, 119:909-920. DOI: 10.1053/gast.2000.18158
[10] Boyce BF, Xing L. The RANKI/RANK/OPG pathway[J]. Curr Osteoporos Rep, 2007, 5:98-104. DOI: 10.1007/s11914-007-0024-y
[11] Bernstein CN, Sargent M, and Leslie WD. Serum osteopro- tegerin is increased in Crohn's disease: a population-based case control study[J]. Inflamm Bowel Dis, 2005, 11: 325-330. DOI: 10.1097/01.MIB.0000164015.60795.ca
[12] Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss[J]. Gut, 2005, 54:479-487. DOI: 10.1136/gut.2004.044370
[13] Hofbauer LC, Lacey DL, Dunstan CR, et al. Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells[J]. Bone, 1999, 25:255-259. DOI: 10.1016/S8756-3282(99)00162-3
[14] Miheller P, Muzes G, Racz K, et al. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy[J]. Inflamm Bowel Dis, 2007, 13 : 1379-1384. DOI: 10.1002/ibd.20234
[15] Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development[J]. Cell, 2001, 107:513-523. DOI: 10.1016/S0092-8674(01)00571-2
[16] Mizuguchi T, Furuta I, Watanabe Y, et al. LRP5, low- density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density[J]. J Hum Genet, 2004, 49:80-86. DOI: 10.1007/s10038-003-0111-6
[17] Todhunter CE, Sutherland-Craggs A, Bartram SA, et al. Influence of IL-6, COL1 Al, and VDR gene polymorphisms on bone mineral density in Crohn's disease[J]. Gut, 2005, 54:1579-1584. DOI: 10.1136/gut.2005.064212
[18] Asomaning K, Bertone-Johnson ER, Nasca PC, et al. The association between body mass index and osteoporosis in patients referred for a bone mineral density examination[J]. J Womens Health (Larchmt), 2006, 15 : 1028-1034. DOI: 10.1089/jwh.2006.15.1028
[19] 刘建彬, 高翔, 张芳宾, 等.炎症性肠病并发低骨量/骨质疏松的危险因素分析[J].中华内科杂志, 2009, 48: 833-836. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk200910013 [20] 张文燕, 袁耀宗.炎症性肠病患者骨代谢状况评估[J].中华消化杂志, 2009, 29:437-441. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhxhzz200907002 [21] Silvennoinen J, Lamberg-Allardt C, Karkkainen M, et al. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease[J]. J Intern Med, 1996, 240:285-292. DOI: 10.1046/j.1365-2796.1996.25862000.x
[22] Gilman J, Shanahan F, and Cashman KD. Determinants of vitamin D status in adult Crohn. disease patients, with particular emphasis on supplemental vitamin D use[J]. Eur J Clin Nutr, 2006, 60:889-896. DOI: 10.1038/sj.ejcn.1602395
[23] Cashman KD, Shanahan F. Is nutrition an aetiological factor for inflammatory bowel disease?[J]. Eur J Gastroenterol Hepatol, 2003, 15:607-613. DOI: 10.1097/00042737-200306000-00005
[24] 罗林枝, 徐苓.维生素K与骨质疏松[J].中国医学科学院学报, 2003, 25:346-349. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgyxkxyxb200303026 [25] Duggan P, O'Brien M, Kiely M, et al. Vitamin K status in patients with Crohn. disease and relationship to bone turnover[J]. Am J Gastroenterol, 2004, 99:2178-2185. DOI: 10.1111/j.1572-0241.2004.40071.x
[26] Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases[J]. Gastroenterology, 2003, 124:795-841. DOI: 10.1053/gast.2003.50106
[27] Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology[J]. Gut, 2000, 46 Suppl 1 : il-8. https://www.ncbi.nlm.nih.gov/pubmed/10647595
[28] Palomba S, Manguso F, Orio F Jr, et al. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study[J]. Menopause, 2008, 15 (4 Pt 1) :730-736. http://cn.bing.com/academic/profile?id=8d467942f11b3d678b9c40eb86bf48bf&encoded=0&v=paper_preview&mkt=zh-cn
[29] Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis : the prevent recur- rence of osteoporotic fractures study. PROOF Study Group[J]. Am J Med, 2000, 109:267-276. DOI: 10.1016/S0002-9343(00)00490-3
[30] Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures[J]. Calcif Tissue Int, 2008, 82:249-257. DOI: 10.1007/s00223-008-9124-7
[31] Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease[J]. Clin Gastroenterol Hepatol, 2005, 3:113-121. DOI: 10.1016/S1542-3565(04)00662-7
[32] Reffitt DM, Meenan J, Sanderson JD, et al. Bone density improves with disease remission in patients with inflammatory bowel disease[J]. Eur J Gastroenterol Hepatol, 2003, 15 : 1267-1273. DOI: 10.1097/00042737-200312000-00003
[33] Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease[J]. Aliment Pharmacol Ther, 2004, 20: 607-614. DOI: 10.1111/j.1365-2036.2004.02152.x
[34] Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn. disease[J]. J Clin Gastroenterol, 2006, 40:55-63. DOI: 10.1097/01.mcg.0000190762.80615.d4
[35] Ryan BM, Russel MG, Schurgers L, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn. disease : a prospective study[J]. Aliment Pharmacol Ther, 2004, 20:851-857. DOI: 10.1111/j.1365-2036.2004.02097.x
[36] Pazianas M, Rhim AD, Weinberg AM, et al. The effect of anti-TNF-alpha therapy on spinal bone mineral density in parents with Crohn's disease[J]. Ann NY Acad Sci, 2006, 1068:543-556. DOI: 10.1196/annals.1346.055
计量
- 文章访问数: 294
- HTML全文浏览量: 163
- PDF下载量: 50
下载:
